Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Abstract Text:

Pei-Xian Mao,Yi-Lang Tang,Feng Jiang,Liang Shu,Xiuling Gu,Ming Li,Mincai Qian,Cui Ma,Philip B Mitchell,Zhuo-Ji Cai,Pei-Xian Mao,Yi-Lang Tang,Feng Jiang,Liang Shu,Xiuling Gu,Ming Li,Mincai Qian,Cui Ma,Philip B Mitchell,Zhuo-Ji Cai,

Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Asberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17: "depressed mood" (P =.023) and "work and interest" (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest." Depression and Anxiety 0:1-9, 2006. (c) 2006 Wiley-Liss, Inc.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Publishing Authors By Initials

PX Mao,YL Tang,F Jiang,L Shu,X Gu,M Li,M Qian,C Ma,PB Mitchell,ZJ Cai,PX Mao,YL Tang,F Jiang,L Shu,X Gu,M Li,M Qian,C Ma,PB Mitchell,ZJ Cai,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Depression and anxiety

VOLUME: 25

Page Numbers: 46-54

Journal Abbreviation:

ISSN: 1091-4269

DAY: 28

MONTH: 01

YEAR: 2008

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9708816

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

AFFILIATION: Beijing Anding Hospital, Capital University of Medical Sciences, Beijing, China.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Depress Anxiety

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population Related Publications

• Expression of vascular endothelial growth factor and E26 transformation-specific-1 in breast carcinoma.
• [A related analysis for alpha, beta fibrinogen gene haplotypes and nucleotide polymorphisms associated with the ischemic stroke in Hainan Han population]
• [Advances in researches on genes and their pathophysiological implications of schizophrenia]
• [Application of atomic force microscopy in cell biology]
• [Cytomegalovirus infection of myeloma cell line KM3 and its effect on IL-6 mRNA expression in the cells]
• [Detection of 8-hydroxyguanine in the DNA of the H2O2-treated HL-60 cells by GC/FID]
• [Determination of deoxyribonucleic acid with nitro-tetrazolium chloride blue by resonance light-scattering technique]
• [Determination of dimethyl ether correction factors in gas chromatography with TCD and FID]
• [Determination of liensinine in plasma by high performance liquid chromatography]
• [Determination of prostaglandinum E1 by fluorescence extinction method]
• [Determination of soluble heavy metal Pb, Cd and Cr in water based architectural coatings for indoor decorating and refurbishing materials by ICP-AES]
• [Distribution and germination of Alexandrium sp. cysts in coastal areas of Southeast China Sea]
• [Effect of apoptosis induced by different vitamin E homologous analogues in human hepatoma cells (HepG2)]
• [Effect of apoptosis induced by different vitamin E homologous analogues in human hepatoma cells(HepG2)]
• [Effect of different vitamin E homologous analogues on human hepatoma cell HepG2 proliferation in vitro]
• [Establishment of animal model for in vitro spermatogenesis by heterotopic grafting of neonatal mouse testis.]
• [Experimental study on repair of goat tibia defect with marrow stromal cell and bio-derived bone]
• [Gamma knife radiosurgery for hemangioblastomas: clinical results and pathological findings]
• [Generation of CD14+ dendritic cells in vitro with GM-CSF and IL-4]
• [Nitrogen and phosphorus absorption and growth characteristics of Alexandrium tamarense]
• [Perivascular epithelioid cell tumor (PEComa) of the uterine]
• [Progress in treatment of infantile spasms]
• [Relationship between the IFN-gamma producing cells specific for recipient and acute graft versus host disease]
• [Spectrophotometric studies on and applications of the reaction of copper with 2-hydroxy-3-carboxy-5-sulfobenzenediazoaminoazobenzene]
• [Study on the expressions of basic fibroblast growth factor and nervous growth factor genes in rat cerebral concussion]
• [Study on the level of environmental endocrine disruptors in serum of precocious puberty patients]
• [Surgical treatment of congenital anophthalmia]
• [The comparison between regenerated cortex and primary cortex of Cortex Cinnamomi on description and microscopic characters]
• [The therapeutic effect of early enteral nutrition togather with recombinant human growth hormone on severely scalded rats]
• [Value of lymph node micrometastasis detected by RT-PCR assay in determining the stage of gastric carcinoma]